NurExone Launches Licensing Efforts for ExoTherapy Platform
15 2월 2024 - 6:20AM
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or
“NurExone”), a biopharmaceutical company, announced today the
commencement of efforts to license its proprietary ExoTherapy
platform for creating nanodrugs by loading therapeutic molecular
cargo into exosomes. Exosomes, which have a natural affinity for
inflamed tissues, deliver loaded therapeutic cargo to inflamed
tissues or cells, creating a healing environment. Therapeutic cargo
to be delivered is expected to include different types of small
molecules including miRNA, siRNA, mRNA,
lncRNA, peptides or even synthetic drugs.
The Company’s ExoTherapy platform for
exosome-based therapy production includes: (i) large-scale exosome
production using the Company’s dedicated bioreactor, (ii) synthesis
of therapeutic cargo and (iii) processes to load the therapeutic
cargo, creating nanodrugs. Scientific results and initiatives have
demonstrated efficiency of the Company’s large-scale production
process, its effectiveness of the Company’s proprietary
small-interfering RNA (“siRNA”) sequences as therapeutic cargo and
the technology for loading therapeutic cargo into exosomes. The
Company’s proprietary loading technology is described in a recently
published PCT application entitled "Compositions and Methods for
Loading Extracellular Vesicles", WO/2023/233395.
Dr. Lior Shaltiel, CEO of NurExone, commented,
“Exosomes have the potential to be the ultimate drug delivery
system. A particularly essential component of being able to use
exosomes is developing an efficient and simple process to load them
with therapeutic active ingredients. Our team of researchers has
innovated a proprietary technology for this purpose, for which we
have also applied for a patent. ExoPTEN, for patients with acute
spinal cord injuries, is being developed on our platform, and we
expect great success through licensing our technology for other
indications!”.
According to Dr. Bat Ami Gotliv, the Company’s
intellectual property consultant, “The latest application discloses
and claims novel compositions and methods for loading extracellular
vesicles with active molecules conjugated to hydrophilic compounds
such as carbohydrates or derivatives thereof. This platform assists
in enriching EVs and specifically exosomes with active molecules,
and therefore EVs with high concentrations of active molecules are
obtained. The exosomes carry their selected chemical content inside
cells, and can serve as an excellent drug delivery tool for drugs
that need to penetrate cells’ membrane and accumulate
intracellularly”.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided exosome-based therapies to be delivered,
non-invasively, to patients who have suffered Central Nervous
System injuries. The company’s first product, ExoPTEN for acute
spinal cord injury, was proven to recover motor and sensory
functions in up to 75% of laboratory rats when administered
intranasally. ExoPTEN has received Orphan Drug Designation from the
FDA with first-in-human expected in 2025. The NurExone platform
technology is expected to offer novel solutions to drug companies
interested in noninvasive targeted drug delivery for other
indications.
For additional information, please visit www.nurexone.com or
follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation - CanadaPhone: +1
905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - GermanyPhone:
+49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
forward-looking statements, including statements about the
Company's future plans and intellectual property, the scientific
and development and commercial activities to be carried out by the
company, the efficient loading of exosomes, future potential
manufacturing, clinical, licensing and marketing activities and the
treatment of certain conditions. Wherever possible, words such as
"may", "will", "should", "could", "expect", "plan", "intend",
"anticipate", "believe", "estimate", "predict" or "potential" or
the negative or other variations of these words, or similar words
or phrases, have been used to identify these forward-looking
statements. These statements reflect management's current beliefs
and are based on information currently available to management as
at the date hereof. Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company's early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company's
intellectual property and dependence on the Company's strategic
partners. These factors should be considered carefully and readers
should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press
release are based upon what management believes to be reasonable
assumptions, the Company cannot assure readers that actual results
will be consistent with these forward-looking statements. These
forward-looking statements are made as of the date of this press
release, and the Company assumes no obligation to update or revise
them to reflect new events or circumstances, except as required by
law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024